Dr Isaac Kobrin
After 15 years in academic medicine as an internist both in Israel and the USA, Dr Kobrin joined the clinical cardiovascular development department at Hoffmann-La Roche in 1989. During his 10 years at Roche (Basel, Switzerland and Nutley, NJ, USA) he was responsible for the worldwide clinical development of key compounds within the company's cardiovascular portfolio from preclinical to launch. In 1997 he became the Global Group Leader of the cardiovascular development group.
In September 1999, Dr Kobrin joined Actelion Pharmaceuticals (Basel, Switzerland) as Senior Vice President, Head of Clinical Development, and member of Actelion's Executive Committee. In July 2009, he became Chief Medical Officer and chairman of the Strategic and Portfolio Board of Actelion.
During the 23 years in the Pharma Industry, 3 drugs were approved under his direct leadership for multiple indications and he was directly involved in numerous regulatory interactions with the FDA and the EMEA/CHMP. Dr Kobrin led three successful (positive voting) meetings with the Advisory Board to the FDA and his contribution was key in the success story of Actelion. In addition, he was directly involved in investor relations and business development activities.
Since February 2012 he is dedicating his time to support, mentor and advise early and late stage Biotech companies.